Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2006 Feb;6(2):217-24.

MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma.

Author information

1
Northwick Park Hospital, Harrow, HA1 3UJ, UK. dam1003@cam.ac.uk

Abstract

Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood. Treatment requires a multimodality approach combining chemotherapy with surgery and radiotherapy. Although overall outcomes have improved considerably, the outlook for patients with high-risk disease, particularly the alveolar subtype, remains bleak and there is a clear need for new chemotherapeutic strategies. This review focuses on the possibilities for interventions targeting myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN). The importance of aberrant expression of this oncogene is well established in neuroblastoma and recent data indicate that MYCN deregulation also occurs in up to a quarter of alveolar subtype cases. A range of possible approaches to target MYCN is discussed, including nucleic acid-based and immunotherapy strategies.

PMID:
16445374
DOI:
10.1586/14737140.6.2.217
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center